Loading people...
Joel Dudley is a Partner at Innovation Endeavors, a venture capital firm. He is a prominent figure in healthcare, biotechnology, and artificial intelligence, known for his expertise in precision medicine, genomics, and data science. He previously served as Chief Scientific Officer at Mount Sinai Health System.
Joel Dudley invests in early-stage companies at the intersection of healthcare, biotechnology, and artificial intelligence. His focus areas include precision medicine, genomics, digital health, AI-driven drug discovery, diagnostics, and other advanced biotechnologies.
Joel Dudley works as a Partner at Innovation Endeavors, a venture capital firm that invests in visionary founders and disruptive technologies across various sectors, with a strong focus on healthcare and life sciences.
Joel Dudley is a distinguished Partner at Innovation Endeavors, where he plays a pivotal role in shaping the future of healthcare and life sciences through strategic venture investments. With a profound background in genomics, data science, and artificial intelligence, Joel brings a unique blend of scientific rigor and entrepreneurial vision to the firm. His work at Innovation Endeavors centers on identifying and supporting early-stage companies that are leveraging cutting-edge technologies to revolutionize patient care, drug development, and health outcomes.
At Innovation Endeavors, Joel Dudley's investment focus areas are deeply rooted in his extensive expertise. He is particularly interested in companies that harness AI and machine learning for drug discovery, diagnostics, and personalized treatment strategies. His portfolio interests also include genomics, precision medicine, digital health platforms, and advanced biotechnologies that promise to transform our understanding and management of disease. Joel is known for his ability to spot disruptive innovations that can scale and create significant impact within the complex healthcare ecosystem.
Before joining Innovation Endeavors, Joel Dudley built an impressive career marked by significant contributions to both academia and industry. He previously served as the Chief Scientific Officer for the Mount Sinai Health System and was a Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. In these roles, he spearheaded initiatives in precision medicine and data-driven healthcare, establishing himself as a thought leader in the field. His academic work focused on integrating diverse data types, including genomic, clinical, and environmental data, to predict disease risk and personalize therapies.
Joel is also a serial entrepreneur and co-founder of several successful ventures. He co-founded Sema4 (now GeneDx), a leading health intelligence company, and NuMedii, an AI-driven drug discovery company. His involvement extends to serving on the boards of innovative companies such as Kallyope and Freenome, both of which are part of the Innovation Endeavors portfolio. These experiences underscore his commitment to translating scientific breakthroughs into tangible healthcare solutions. Through his leadership at Innovation Endeavors, Joel Dudley continues to empower visionary founders who are building the next generation of healthcare companies.
Joel Dudley is a Partner at Innovation Endeavors in the San Francisco Bay Area, where he leads investments in life sciences and computational biology. Prior to joining the venture capital firm in January 2022, he served as the Chief Scientific Officer at Tempus Labs, a precision medicine company that completed its initial public offering in June 2024. Dudley previously worked as a tenured Professor of Genetics and Genomic Sciences and the founding Director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai. As an entrepreneur, he co-founded NuMedii and Onegevity Health, the latter of which was acquired by Thorne, and he has co-authored more than 150 peer-reviewed scientific papers. Holding a doctorate in biomedical informatics from Stanford University, Dudley currently focuses on the intersection of artificial intelligence, genomics, and early-stage biotechnology startups.
